Literature DB >> 9499052

Nucleocapsid and matrix protein contributions to selective human immunodeficiency virus type 1 genomic RNA packaging.

D T Poon1, G Li, A Aldovini.   

Abstract

The nucleocapsid protein (NC) of retroviruses plays a major role in genomic RNA packaging, and some evidence has implicated the matrix protein (MA) of certain retroviruses in viral RNA binding. To further investigate the role of NC in the selective recognition of genomic viral RNA and to address the potential contribution of MA in this process, we constructed chimeric and deletion human immunodeficiency virus type 1 (HIV-1) mutants that alter the NC or MA protein. Both HIV and mouse mammary tumor virus (MMTV) NC proteins have two zinc-binding domains and similar basic amino acid compositions but differ substantially in total length, amino acid sequence, and spacing of the zinc-binding motifs. When the entire NC coding sequence of HIV was replaced with the MMTV NC coding sequence, we found that the HIV genome was incorporated into virions at 50% of wild-type levels. Viruses produced from chimeric HIV genomes with complete NC replacements, or with the two NC zinc-binding domains replaced with MMTV sequences, preferentially incorporated HIV genomes when both HIV and MMTV genomes were simultaneously present in the cell. Viruses produced from chimeric MMTV genomes in which the MMTV NC had been replaced with HIV NC preferentially incorporated MMTV genomes when both HIV and MMTV genomes were simultaneously present in the cell. In contrast, viruses produced from chimeric HIV genomes containing the Moloney NC, which contains a single zinc-binding motif, were previously shown to preferentially incorporate Moloney genomic RNA. Taken together, these results indicate that an NC protein with two zinc-binding motifs is required for specific HIV RNA packaging and that the amino acid context of these motifs, while contributing to the process, is less crucial for specificity. The data also suggest that HIV NC may not be the exclusive determinant of RNA selectivity. Analysis of an HIV MA mutant revealed that specific RNA packaging does not require MA protein.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9499052      PMCID: PMC109491          DOI: 10.1128/JVI.72.3.1983-1993.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

2.  Characterization of Moloney murine leukemia virus mutants with single-amino-acid substitutions in the Cys-His box of the nucleocapsid protein.

Authors:  C Méric; S P Goff
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Nucleotide sequence of Moloney murine leukaemia virus.

Authors:  T M Shinnick; R A Lerner; J G Sutcliffe
Journal:  Nature       Date:  1981 Oct 15-21       Impact factor: 49.962

5.  Binding sites of viral protein P19 onto Rous sarcoma virus RNA and possible controls of viral functions.

Authors:  J L Darlix; P F Spahr
Journal:  J Mol Biol       Date:  1982-09-15       Impact factor: 5.469

6.  Rous sarcoma virus p19 binds to specific double-stranded regions of viral RNA: effect of p19 on cleavage of viral RNA by RNase III.

Authors:  J P Leis; J McGinnis; R W Green
Journal:  Virology       Date:  1978-01       Impact factor: 3.616

7.  Correlation of RNA binding affinity of avian oncornavirus p19 proteins with the extent of processing of virus genome RNA in cells.

Authors:  J P Leis; P Scheible; R E Smith
Journal:  J Virol       Date:  1980-09       Impact factor: 5.103

8.  A molecular clone of HTLV-III with biological activity.

Authors:  A G Fisher; E Collalti; L Ratner; R C Gallo; F Wong-Staal
Journal:  Nature       Date:  1985 Jul 18-24       Impact factor: 49.962

9.  Isolation of T-cell tropic HTLV-III-like retrovirus from macaques.

Authors:  M D Daniel; N L Letvin; N W King; M Kannagi; P K Sehgal; R D Hunt; P J Kanki; M Essex; R C Desrosiers
Journal:  Science       Date:  1985-06-07       Impact factor: 47.728

10.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  30 in total

1.  Functional replacement of nucleocapsid flanking regions by heterologous counterparts with divergent primary sequences: effects of chimeric nucleocapsid on the retroviral replication cycle.

Authors:  William Fu; Wei-Shau Hu
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  RNA incorporation is critical for retroviral particle integrity after cell membrane assembly of Gag complexes.

Authors:  Shainn-Wei Wang; Anna Aldovini
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  Nucleocapsid-RNA interactions are essential to structural stability but not to assembly of retroviruses.

Authors:  Shainn-Wei Wang; Kristin Noonan; Anna Aldovini
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

4.  Targeted nuclear import of open reading frame 1 protein is required for in vivo retrotransposition of a telomere-specific non-long terminal repeat retrotransposon, SART1.

Authors:  Takumi Matsumoto; Hidekazu Takahashi; Haruhiko Fujiwara
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

5.  Evolution of feline immunodeficiency virus Gag proteins.

Authors:  Evan Burkala; Mary Poss
Journal:  Virus Genes       Date:  2007-01-30       Impact factor: 2.332

Review 6.  Nucleocapsid protein function in early infection processes.

Authors:  James A Thomas; Robert J Gorelick
Journal:  Virus Res       Date:  2008-02-14       Impact factor: 3.303

7.  The double-stranded RNA-binding protein Staufen is incorporated in human immunodeficiency virus type 1: evidence for a role in genomic RNA encapsidation.

Authors:  A J Mouland; J Mercier; M Luo; L Bernier; L DesGroseillers; E A Cohen
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

8.  Solution structure and backbone dynamics of Mason-Pfizer monkey virus (MPMV) nucleocapsid protein.

Authors:  Y Gao; K Kaluarachchi; D P Giedroc
Journal:  Protein Sci       Date:  1998-11       Impact factor: 6.725

9.  Opposing mechanisms involving RNA and lipids regulate HIV-1 Gag membrane binding through the highly basic region of the matrix domain.

Authors:  Vineela Chukkapalli; Seung J Oh; Akira Ono
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

10.  Human immunodeficiency virus type 1 protease triggers a myristoyl switch that modulates membrane binding of Pr55(gag) and p17MA.

Authors:  L Hermida-Matsumoto; M D Resh
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.